| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1958 | 2020 |
| Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma DA Braun, Y Hou, Z Bakouny, M Ficial, M Sant’Angelo, J Forman, ... Nature medicine 26 (6), 909-918, 2020 | 730 | 2020 |
| Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma K Bi, MX He, Z Bakouny, A Kanodia, S Napolitano, J Wu, G Grimaldi, ... Cancer Cell 39 (5), 649-661. e5, 2021 | 425 | 2021 |
| Progressive immune dysfunction with advancing disease stage in renal cell carcinoma DA Braun, K Street, KP Burke, DL Cookmeyer, T Denize, CB Pedersen, ... Cancer Cell 39 (5), 632-648. e8, 2021 | 329 | 2021 |
| Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of Oncology, 2021 | 322 | 2021 |
| COVID-19 and cancer: current challenges and perspectives Z Bakouny, JE Hawley, TK Choueiri, S Peters, BI Rini, JL Warner, ... Cancer Cell 38 (5), 629-646, 2020 | 296 | 2020 |
| Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma DA Braun, Z Bakouny, L Hirsch, R Flippot, EM Van Allen, CJ Wu, ... Nature Reviews Clinical Oncology, 1-16, 2021 | 258 | 2021 |
| Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic Z Bakouny, M Paciotti, AL Schmidt, SR Lipsitz, TK Choueiri, QD Trinh JAMA oncology 7 (3), 458-460, 2021 | 255 | 2021 |
| Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes PV Nuzzo, JE Berchuck, K Korthauer, S Spisak, AH Nassar, S Abou Alaiwi, ... Nature Medicine 26 (7), 1041-1043, 2020 | 251 | 2020 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 188 | 2021 |
| Transcriptional mediators of treatment resistance in lethal prostate cancer MX He, MS Cuoco, J Crowdis, A Bosma-Moody, Z Zhang, K Bi, A Kanodia, ... Nature Medicine 27 (3), 426-433, 2021 | 148 | 2021 |
| Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and Cancer Consortium (CCC19) cohort study DR Rivera, S Peters, OA Panagiotou, DP Shah, NM Kuderer, CY Hsu, ... Cancer discovery 10 (10), 1514-1527, 2020 | 145 | 2020 |
| Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features BA McGregor, RR McKay, DA Braun, L Werner, K Gray, A Flaifel, ... Journal of Clinical Oncology 38 (1), 63-70, 2020 | 140 | 2020 |
| Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma Z Bakouny, DA Braun, SA Shukla, W Pan, X Gao, Y Hou, A Flaifel, S Tang, ... Nature communications 12 (1), 808, 2021 | 122 | 2021 |
| Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma P Ravi, C Mantia, C Su, K Sorenson, D Elhag, N Rathi, Z Bakouny, ... JAMA oncology 6 (10), 1606-1610, 2020 | 112 | 2020 |
| IL-8 and cancer prognosis on immunotherapy Z Bakouny, TK Choueiri Nature Medicine 26 (5), 650-651, 2020 | 111 | 2020 |
| COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer AL Schmidt, C Labaki, CY Hsu, Z Bakouny, N Balanchivadze, SA Berg, ... Annals of Oncology, 2021 | 101 | 2021 |
| Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the … Z Bakouny, T El Zarif, S Dudani, JC Wells, CL Gan, F Donskov, J Shapiro, ... European Urology 83 (2), 145-151, 2023 | 86 | 2023 |
| Integrative clinical and molecular characterization of translocation renal cell carcinoma Z Bakouny, A Sadagopan, P Ravi, NY Metaferia, J Li, S AbuHammad, ... Cell Reports 38 (1), 110190, 2022 | 82 | 2022 |
| Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma S Abou Alaiwi, W Xie, AH Nassar, S Dudani, D Martini, Z Bakouny, ... Journal for ImmunoTherapy of Cancer 8 (1), 2020 | 81 | 2020 |
Toni ChoueiriDana-Farber Cancer InstituteZweryfikowany adres z dfci.harvard.edu